Androgen Deprivation Therapy ADT Market Share 2021: Global Trends, Key Players, Industry Analysis Report to 2027

The Androgen Deprivation Therapy ADT Market size is expected to grow at an annual average of 5% during 2021-2027. Androgen deprivation therapy (ADT), also known as androgen suppression therapy, is administered to men with prostate cancer. The pancreas is an androgen-dependent organ, and by providing ADT, it can provide treatment for advanced and metastatic disease. ADT is also used in combination with external beam radiation therapy (EBRT) to improve response to radiation in patients with moderate to high-risk prostate cancer. It is estimated that approximately 40% of patients diagnosed with prostate cancer will receive ADT within 6 months of diagnosis.

The following segmentation are covered in this report:

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Route of Administration

• Oral
• Injectable

Company Profile

• Pfizer
• Astellas Pharma
• Johnson and Johnson
• Novartis International
• Merck
• Veru
• Sanofi
• GlaxoSmithKline
• Bayer
• Orion
• AstraZeneca

Scope of the report

The research study analyses the Androgen Deprivation Therapy ADT Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Androgen Deprivation Therapy ADT Market Report

• What was the Androgen Deprivation Therapy ADT Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027)
• What will be the CAGR of Market during the forecast period (2021-2027)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
• Which manufacturer/vendor/players in the Androgen Deprivation Therapy ADT Market was the market leader in 2020?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.